Italy’s Chiesi Looks to Top Its Biggest M&A Deal as Sales Expand

Italian biopharmaceuticals company Chiesi Group is scouring the market for new acquisition targets to keep up the pace of its growth in respiratory and rare disease treatments.

Chiesi reported €3.4 billion ($3.8 billion) in revenue for 2024, up 13% at constant exchange rates, with profitability close to 30%, it said in a statement on Wednesday.

Sales at the global rare diseases business grew 41% to €763 million with the launch of new products in the US and the integration of Amryt Pharma, purchased in 2023 for as much as $1.48 billion.

Now, the firm is looking to top that ...